CenterBook Partners LP Purchases 2,797 Shares of Cencora, Inc. $COR

CenterBook Partners LP raised its position in shares of Cencora, Inc. (NYSE:COR) by 56.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,722 shares of the company’s stock after purchasing an additional 2,797 shares during the quarter. CenterBook Partners LP’s holdings in Cencora were worth $2,608,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COR. Oakworth Capital Inc. purchased a new stake in Cencora in the 4th quarter worth $26,000. Elyxium Wealth LLC purchased a new stake in shares of Cencora during the fourth quarter worth about $27,000. Archer Investment Corp raised its stake in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the period. IAG Wealth Partners LLC purchased a new position in Cencora in the 3rd quarter worth approximately $30,000. Finally, Caitlin John LLC bought a new position in Cencora in the 3rd quarter worth approximately $31,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Up 1.8%

Shares of NYSE COR opened at $279.15 on Wednesday. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The business’s 50 day moving average is $291.16 and its two-hundred day moving average is $329.11. The stock has a market capitalization of $54.31 billion, a P/E ratio of 21.41, a PEG ratio of 1.48 and a beta of 0.59.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter last year, the firm posted $4.42 EPS. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, research analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its board has initiated a stock buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s payout ratio is 18.40%.

Wall Street Analyst Weigh In

COR has been the topic of several recent analyst reports. Evercore set a $360.00 price objective on shares of Cencora in a research report on Wednesday, April 8th. UBS Group raised their target price on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. JPMorgan Chase & Co. boosted their target price on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Finally, Citigroup dropped their price target on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.